Unknown

Dataset Information

0

Extended release niacin-laropiprant in patients with hypercholesterolemia or mixed dyslipidemias improves clinical parameters.


ABSTRACT: The progression of atherosclerosis remains a major cause of morbidity and mortality. Plaque formation is an immunological response driven by a number of risk factors, and reduction of risk is the primary goal of treatment. The role of LDL-C is well established and statins have proved effective drugs, although the relative risk reduction is only around 30%. The importance of other factors-notably low HDL-C and high TGs-has become increasingly clear and the search for alternative strategies continues. Niacin is particularly effective in achieving normalization of HDL-C but is clinically underutilized due to the side effect of cutaneous flushing. The discovery that flushing is mediated by mechanisms distinct from the lipid-lowering effects has led to the development of combination drugs with reduced side effects. This review considers the evidence regarding the clinical efficacy of extended-release niacin and the DP1 antagonist laropiprant in the treatment of hypercholesterolemia and mixed dyslipidemias.

SUBMITTER: Vosper H 

PROVIDER: S-EPMC3201109 | biostudies-other | 2011

REPOSITORIES: biostudies-other

altmetric image

Publications

Extended release niacin-laropiprant in patients with hypercholesterolemia or mixed dyslipidemias improves clinical parameters.

Vosper Helen H  

Clinical Medicine Insights. Cardiology 20110919


The progression of atherosclerosis remains a major cause of morbidity and mortality. Plaque formation is an immunological response driven by a number of risk factors, and reduction of risk is the primary goal of treatment. The role of LDL-C is well established and statins have proved effective drugs, although the relative risk reduction is only around 30%. The importance of other factors-notably low HDL-C and high TGs-has become increasingly clear and the search for alternative strategies contin  ...[more]

Similar Datasets

| S-EPMC3108693 | biostudies-other
| S-EPMC4170918 | biostudies-literature
| S-EPMC3828803 | biostudies-literature
| S-EPMC6985042 | biostudies-literature
| S-EPMC2408654 | biostudies-literature
| S-EPMC5753310 | biostudies-other
| S-EPMC3308290 | biostudies-literature
| S-EPMC4914402 | biostudies-literature
| S-EPMC3586144 | biostudies-other
| S-EPMC4942972 | biostudies-literature